+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)



Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)



Current Medicinal Chemistry 24(1): 57-64



c-Met, also known as the surface receptor of hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase with heterodimer transmembrane. c-Met involves in the activation of several signaling pathways, most of them are implicated in aggressive cancer phenotypes. In a variety of human malignances, c-Met/HGF signaling has been found aberrant, and in many instances, has been correlated with advanced disease stage and poor prognosis. Thus, the c-Met has identified as an emerging and interesting target for cancer chemotherapy. In this review, we briefly summarize signaling pathways of c-Met, and discuss the crystal structures of representative c-Met and the binding modes with their ligands. We also present updates on the design, synthesis and structure-activity relationship analysis of c-Met inhibitors developed from 2014 till now. At last, we review the c-Met inhibitors that are in clinical development and highlight the future prospects.

(PDF emailed within 1 workday: $29.90)

Accession: 058706307

Download citation: RISBibTeXText

PMID: 27804876


Related references

Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. Current Drug Targets 13(11): 1432-1444, 2013

Recent advances in the development of catalytic inhibitors of human DNA topoisomerase II╬▒ as novel anticancer agents. Current Medicinal Chemistry 20(5): 694-709, 2014

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17(8): 1470-1481, 2003

Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. Chemistry and Biology 21(11): 1433-1443, 2015

Combinatorial approaches in anticancer drug discovery: recent advances in design and synthesis. Current Medicinal Chemistry 8(12): 1383-1404, 2001

Combinatorial Approaches in Anticancer Drug Discovery: Recent Advances in Design and Synthesis. Frontiers in Medicinal Chemistry - Online 1(1): 215-235, 2004

Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents. Bioorganic Chemistry 79: 277-284, 2018

Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents. Current Medicinal Chemistry 19(34): 5885-5894, 2013

Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. Current Medicinal Chemistry 7(10): 1081-1100, 2000

Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. European Journal of Medicinal Chemistry 168: 315-329, 2019

Design, Synthesis, and Evaluation of a New Series of Thiazole-Based Anticancer Agents as Potent Akt Inhibitors. Molecules 23(6), 2018

Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. Bioorganic and Medicinal Chemistry 17(16): 5974-5982, 2009

Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents. Medchemcomm 9(5): 795-811, 2018

Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents. Acs Medicinal Chemistry Letters 10(4): 499-503, 2019

Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. Journal of Medicinal Chemistry 53(24): 8716-8726, 2011